Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United Laboratories International HoldingsSTU:UNJ 65 Dividend Payout Ratio is 17.67 as of Dec. 2025, which is 9717% above its 10-year median of 0.18. GuruFocus rates STU:UNJ with a GF Score™ of 65/100 and a GF Value™ of €0.93 (Fairly Valued). The stock has 5 warning signs investors should review. Among 445 Drug Manufacturers companies, United Laboratories International Holdings ranks worse than 56.63% on this metric.
During the past 13 years, the highest Trailing Annual Dividend Yield of United Laboratories International Holdings was 5.92%. The lowest was 0.74%. And the median was 2.56%.
During the past 12 months, United Laboratories International Holdings's average Dividends Per Share Growth Rate was 2.50% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 49.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 45.10% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of United Laboratories International Holdings was 51.40% per year. The lowest was 7.90% per year. And the median was 41.70% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
United Laboratories International Holdings (STU:UNJ) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
United Laboratories International Holdings Dividend Payout Ratio Related Terms
United Laboratories International Holdings Dividend Payout Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings Dividend Payout Ratio Chart
United Laboratories International Holdings Annual Data
STU:UNJ vs ZTS, UTHR: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings Dividend Payout Ratio vs Drug Manufacturers Industry
United Laboratories International Holdings Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (STU:UNJ) has a Dividend Payout Ratio of 17.67 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on United Laboratories International Holdings and its competitors. This is 9717% above median its historical median of 0.18. Over the past decade, United Laboratories International Holdings' Dividend Payout Ratio has ranged from 0.13 to 0.43. According to the industry distribution chart, United Laboratories International Holdings ranks #252 out of 445 companies in the Drug Manufacturers industry, placing it in the top 56.6%.
Is United Laboratories International Holdings' Dividend Payout Ratio too high?
United Laboratories International Holdings' current Dividend Payout Ratio of 17.67 is 9717% above median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.43. The Drug Manufacturers industry median Dividend Payout Ratio is 0.38. United Laboratories International Holdings' value of 17.67 is 4550% above this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #252 out of 445 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, United Laboratories International Holdings has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #252 out of 445 companies for Dividend Payout Ratio. This places United Laboratories International Holdings in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. United Laboratories International Holdings' value of 17.67 is 4550% above this benchmark. Historically, United Laboratories International Holdings' own Dividend Payout Ratio has ranged from 0.13 to 0.43 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 0.38, United Laboratories International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 445 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current Dividend Payout Ratio of 17.67 is 4550% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current Dividend Payout Ratio is 17.67, which is 9717% above median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (STU:UNJ) is currently considered Fairly Valued. The stock's GF Value™ is €0.93, compared to a current price of €1.00 — trading 7% above its estimated fair value. The current Dividend Payout Ratio is 17.67, which is 9717% above median its 10-year median of 0.18 and 4550% above the Drug Manufacturers industry median of 0.38. United Laboratories International Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For United Laboratories International Holdings (STU:UNJ), the current Dividend Payout Ratio is 17.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (STU:UNJ) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be overvalued.
The current stock price of €1.00 is trading 7% above its estimated GF Value™ of €0.93.
GuruFocus considers United Laboratories International Holdings to be Fairly Valued.
Key valuation signals for STU:UNJ:
Dividend Payout Ratio: 17.67 (9717% above median its 10-year median of 0.18)
GF Value™: €0.93 vs. price of €1.00 (7% above fair value)
Industry Position: 4550% above the Drug Manufacturers median (#252 of 445)
No single metric tells the full story. See the STU:UNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Business Description
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
65GF Score
Get the complete analysis for STU:UNJ
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNJ has been successfully added to your 
